SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — John Henry Holliday

PatientJohn Henry Holliday
Date of birth2004-08-14
IdentifiersMRN HR-NI007-SYN; SSN (made up) 000-07-8153
Document date2026-03-17
AuthorMartin Beaumont, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Five-week review: susceptibility results, release from isolation, and liver monitoring. [S]

History of Present Illness

Mr. Holliday returns five weeks into treatment. The isolate is susceptible to isoniazid, rifampin, pyrazinamide, and ethambutol, and ethambutol was stopped a week ago when the result arrived. The three sputum smears collected in the third week were negative, and with his clinical improvement and more than two weeks of treatment he was released from home isolation two weeks ago and returned to work the following week. His cough is now occasional and dry, and the night sweats have stopped. He has taken every dose by video. He has no nausea now, no yellowing, dark urine, abdominal pain, numbness, or vision change. He has not had a drink in three weeks and has met his counselor twice. His roommate's first blood test was negative and will be repeated by the health department. [S]

ElementDetail
SusceptibilitySusceptible to all four first-line drugs; ethambutol stopped a week ago
Infection controlThree negative smears; released from isolation and back at work
SymptomsOccasional dry cough; no night sweats
AlcoholNone for three weeks; two counseling sessions

Review of Systems

SystemResultFinding
RespiratoryPositiveOccasional dry cough; no sputum or blood
ConstitutionalNegativeNo fever or night sweats; appetite good
GastrointestinalNegativeNo nausea, abdominal pain, or jaundice
PsychiatricNegativeMood better since returning to work; no thoughts of suicide or self-harm

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Isoniazid 300 mg tablet, one tablet daily300 mg once daily by video-observed therapy with the health department, seven days a week, for six monthsOral route2026-02-12 to 2026-08-13completedS
Rifampin 300 mg capsules, two capsules (600 mg) daily600 mg once daily on an empty stomach by video-observed therapy with the health department, seven days a week, for six monthsOral route2026-02-12 to 2026-08-13completedS
Pyrazinamide 500 mg tablets, three tablets (1500 mg) daily1500 mg once daily by video-observed therapy with the health department, seven days a week, for the eight-week intensive phaseOral route2026-02-12 to 2026-04-08completedS
Ethambutol 400 mg tablets, three tablets (1200 mg) daily1200 mg once daily by video-observed therapy with the health department, seven days a week, until susceptibility results returnOral route2026-02-12 to 2026-03-10stoppedS
Vitamin B6 (pyridoxine) 50 mg tablet, one tablet daily50 mg once daily with isoniazidOral route2026-02-12 to 2026-08-13completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-03-17Body height178cmS
2026-03-17Body weight61kgS
2026-03-17Body mass index (BMI) [Ratio]19.3kg/m2S
2026-03-17Systolic blood pressure116mm[Hg]S
2026-03-17Diastolic blood pressure72mm[Hg]S
2026-03-17Heart rate84/minS
2026-03-17Respiratory rate16/minS
2026-03-17Body temperature36.8CelS
2026-03-17Oxygen saturation in Arterial blood by Pulse oximetry97%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-03-17Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma52U/L7-56 U/LNormalS
2026-03-17Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma47U/L10-40 U/LHighS
2026-03-17Bilirubin.total [Mass/volume] in Serum or Plasma0.8mg/dL0.1-1.2 mg/dLNormalS
2026-03-17Total score [AUDIT-C]2{score}S

Physical Exam

Vital signs recorded on 2026-03-17; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 61.0 kg; temperature 36.8 °C
EyesNo icterus
RespiratoryA few crackles at the right apex; no bronchial breathing
AbdomenSoft; liver not enlarged or tender
NeurologicalNormal sensation in the feet

Problems

ProblemClinical statusVerificationCodeProvenance
Pulmonary tuberculosis, right upper lobe cavitary, sputum smear-positive, confirmed by nucleic acid amplification without rifampin resistanceactiveconfirmed A15.0S — Synthetic modern coding of his documented pulmonary tuberculosis at the time of diagnosis; the bacteriology is synthetic.
Alcohol use disorder, mild, with binge drinkingactiveconfirmed F10.10S — Synthetic modern coding anchored to the documented heavy drinking; the severity and the criteria met are synthetic.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationSymptom review: cough, sputum, hemoptysis, fever, night sweatsAt least monthly during treatmentCompleted todayOccasional dry cough only
ExaminationWeightAt least monthly during treatmentCompleted today61.0 kg, up 3.0 kg since diagnosis
Medication safetyHepatitis symptom review (nausea, vomiting, abdominal pain, jaundice, dark urine)Every visit and every observed doseCompleted todayNone
LaboratoryLiver tests (ALT, AST, bilirubin)Baseline, at two weeks, then monthly because of alcohol useCompleted todayALT 52 U/L normal, AST 47 U/L slightly high, bilirubin 0.8 mg/dL normal; no symptoms
ImagingVisual acuity and color visionBaseline and monthly while on ethambutolNot indicatedEthambutol stopped a week ago, after normal checks at baseline and two weeks
LaboratoryDrug susceptibility testing of the first isolateOnce, on the first positive cultureCompleted todaySusceptible to isoniazid, rifampin, pyrazinamide, and ethambutol
LaboratorySputum AFB smear and cultureMonthly until two consecutive cultures are negativeCompleted todayThree smears in the third week negative; cultures from those samples pending
Medication safetyDoses observed and missed (video-observed therapy)Every visitCompleted todayAll doses observed
Medication safetyPeripheral neuropathy check, with pyridoxineEvery visitCompleted todayNo neuropathy
Self-managementHome isolation and the criteria for releaseUntil three negative smears, clinical improvement, and two weeks of treatmentCompleted todayRelease criteria met two weeks ago; back at work, with the health department's agreement
ReferralContact investigation (household, coworkers, patients)Led by the health department, from diagnosisReferredIn progress with the health department
SurveyAlcohol use (AUDIT-C for the past month)Every visitCompleted todayAUDIT-C 2 for the past month; none in three weeks
Self-managementBrief counseling about alcohol and liver riskEvery visitCompleted todayGoal of no alcohol reinforced
ReferralCounseling with a substance-use counselorEvery one to two weeks during treatmentCompleted todayTwo sessions so far
Medication safetyMedication for alcohol use disorderOffered for alcohol use disorderNot indicatedNot wanted; doing well with counseling
SurveySuicide-risk review and safety plan, with the 988 Suicide & Crisis LifelineEvery visitCompleted todayNo thoughts of suicide

Goal progress:

Guideline basis: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016); An official ATS statement: hepatotoxicity of antituberculosis therapy (2006); Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC (2005); VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024)

Follow-up: Two-month review with sputum culture and liver tests. Next scheduled visit 2026-04-14: end of the intensive phase: two-month sputum and the start of the continuation phase. [S]